Agenus (AGEN) Stock Price Down 6.1%
Agenus Inc. (NASDAQ:AGEN) traded down 6.1% during mid-day trading on Tuesday . The company traded as low as $3.35 and last traded at $3.37. 1,907,088 shares changed hands during mid-day trading, an increase of 61% from the average session volume of 1,186,853 shares. The stock had previously closed at $3.59.
A number of equities research analysts have issued reports on the company. Zacks Investment Research raised Agenus from a “hold” rating to a “buy” rating and set a $4.25 price target on the stock in a research report on Wednesday, October 25th. BidaskClub lowered Agenus from a “hold” rating to a “sell” rating in a research report on Saturday, December 9th. Finally, ValuEngine raised Agenus from a “strong sell” rating to a “sell” rating in a research report on Thursday, September 7th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. Agenus has a consensus rating of “Hold” and a consensus target price of $5.81.
The company has a debt-to-equity ratio of -2.39, a quick ratio of 1.55 and a current ratio of 1.55.
Agenus (NASDAQ:AGEN) last issued its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.37) earnings per share for the quarter, hitting the consensus estimate of ($0.37). The business had revenue of $3.40 million for the quarter, compared to analyst estimates of $5.91 million. Agenus’s revenue was down 24.4% on a year-over-year basis. equities research analysts forecast that Agenus Inc. will post -1.19 EPS for the current fiscal year.
In other Agenus news, CEO Garo H. Armen bought 100,000 shares of the business’s stock in a transaction dated Monday, October 30th. The shares were acquired at an average price of $3.55 per share, with a total value of $355,000.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 7.60% of the stock is currently owned by company insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in AGEN. Cubist Systematic Strategies LLC acquired a new position in Agenus during the third quarter worth approximately $134,000. OxFORD Asset Management LLP acquired a new position in Agenus during the second quarter worth approximately $141,000. Voya Investment Management LLC increased its position in Agenus by 18.5% during the second quarter. Voya Investment Management LLC now owns 40,855 shares of the biotechnology company’s stock worth $160,000 after buying an additional 6,381 shares during the period. State of Wisconsin Investment Board acquired a new position in Agenus during the second quarter worth approximately $207,000. Finally, Metropolitan Life Insurance Co. NY increased its position in Agenus by 12.2% during the first quarter. Metropolitan Life Insurance Co. NY now owns 55,920 shares of the biotechnology company’s stock worth $211,000 after buying an additional 6,101 shares during the period. 37.90% of the stock is currently owned by institutional investors.
Agenus Company Profile
Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with Analyst Ratings Network's FREE daily email newsletter.